| Literature DB >> 33816454 |
Lijuan Sun1, Tongyang Li1, Sen Yu1, Mengmeng Mao1, Dagang Guo1.
Abstract
In recent years, ass="Chemical">strontium-substituted calcium phosphate bone cement (Entities:
Keywords: calcium phosphate bone cement; cytocompatibility; hydration reaction; physicochemical property; strontium
Year: 2021 PMID: 33816454 PMCID: PMC8012852 DOI: 10.3389/fbioe.2021.643557
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Several Sr-CPC bone cements in the present available literatures.
| Name | Composition | Hydration products | Major merits and demerits | Literatures |
| Sr-HAP bone cement | Powder phases: TTCP, DCPA, DSPA Liquid phases: PA | Ca10– | Merits: higher compressive strength, 38.2∼66.5 MPa; | |
| Injectable bioactive bone cement | Powder phases: Sr-HAP, reinforcing silica Liquid phases: D-GMA resin | Sr-HAP, D-GMA resin | Merits: excellent injectability and radiopacity. Demerits: lower compressive strength, 7.15 MPa; lower degradation rate for the resin | |
| Calcium strontium HAP cements | Powder phases: TTCP, α-TCP Liquid phases: Strontium nitrate, orthophosphoric acid | Sr-HAP | Merits: easily prepared. Demerits: high dose of impurity ions (NO3–) contained in the final hardened body. | |
| Sr-containing brushite cement | Powder phases: β-TCP, Ca(H2PO4)2, SrCl2, Na4P2O7 Liquid phases: 2M PA solution | Sr-DCPD, unreacted β-TCP | Merits: excellent cohesion and a diametric tensile strength of 5 MPa. Demerits: some Cl– ions remained in the final hardened body and more than 3 powder phases. | |
| Sr modified biocements | Powder phases: Sr-β-TCP, MCPM Liquid phases: Water | Ca(1–0.25 | Merits: good releasing effect of Sr2+ ions. Demerits: the data about its mechanical properties is not available. | |
| Sr-containing CPC | Powder phases: Sr-ACP, DCPA Liquid phases: deionized water | Sr-HAP, unreacted DCPA | Merits: higher compressive strength, 37∼74.9 MPa; porosity, 55.7∼58.2%. Demerits: the setting time is out of clinical requirement, | |
| Newly developed Sr-substituted α-TCP bone cements | Powder phases: Sr-α-TCP Liquid phases: 10 wt.% poly(ethylene glycol), 20 wt.% citric acid solution; or 0.5 wt.% hydroxyl propyl methylcellulose, 10 wt.% poly(ethylene glycol), 20 wt.% citric acid solution | DCPD, unreacted Sr-α-TCP | Merits: expectable degradability. Demerits: lower compressive strength, 13.7 MPa; complex liquid phase composite. | |
| Ca–Sr-mixed phosphate cement | Powder phases: DCPD, CaO, SC Liquid phases: ammonium phosphate buffer | Sr1.35Ca7.65(HPO4) | Merits: enhanced degradation rate of HAP. Demerits: lower compressive strength, 15.5∼20.1 MPa. | |
| A easy-to-prepare Sr(II)-modified CPC | Powder phases:α-TCP, DCPA, CC, SC, HAP Liquid phases: 4 wt.% Na2HPO4 aqueous solution | HAP, CC, SC, α-TCP, monetite | Merits: higher compressive strength, ∼57.7 MPa. Demerits: complex (5) phases in cement powder; longer setting time, | |
| Sr-incorporated CPC | Powder phases: TTCP, DCPA, DSPA Liquid phases: a combination of citric acid and 12 wt.% polyvinylpyrrolidone K-30 | Apatite | Merits: | |
| Radiopaque brushite cements | Powder phases: MCPM, Na2H2P2O7, β-TCP, SrF2/SrI2/SrBr2/SrCl2⋅6H2O Liquid phases: distilled water | DCPD, β-Ca2P2O7, β-TCP, Monetite, unreacted SrF2 | Merits: increased solubility; higher radiopacity. Demerits: lower wet compressive strength, <8 MPa; lower diametral tensile strength, <4 MPa. Complex phases in cement powder. | |
| CPC | Powder phases: Sr-TTCP, DCPA Liquid phases: phosphate buffer solution, trisodium citrate | HAP, remaining TTCP | Merits: higher compressive strength, 38.66∼60.20 MPa; faster degradation rate; suitable setting time, 10∼17 min. Demerits: the data about its biocompatibility is not available. | |
| Sr-enriched gelatin-CPC | Powder phases: gelatin-α-TCP, DCPD, SrCl2⋅6H2O Liquid phases: distilled water | α-TCP, calcium-deficient HAP | Merits: | |
| Sr-containing CPC | Powder phases: TCP, DSPA, SC, HAP Liquid phases: an aqueous solution of 3 M K2HPO4 and 1.5 M KH2PO4 | HAP | Merits: compressive strength, 34 MPa. Demerits: the data about its setting time is not available. | |
| Sr-substituted α-TCP cements | Powder phases: Sr-α-TCP Liquid phases: 2.5wt.% Na2HPO4 accelerating solution | Sr-HAP, unreacted β-TCP. | Merits: good | |
| Sr-loaded mineral bone cements | Powder phases: DCPD, CC, SC Liquid phases: deionized water or Powder phases: DCPD, CC Liquid phases: SrCl2⋅6H2O solution | CC, carbonated apatite, SC or CC, S-HAP | Merits: enhancing cell proliferation. Demerits: lower porosity. | |
| Sr-doped α-TCP bone cement | Powder phases: Sr-Ca8H2(PO4)6⋅5H2O, α-TCP Liquid phases: 100 mM citric acid solution | HAP | Merits: enhancing degradation and Sr ion release. Demerits: the data about its biocompatibility is not available. | |
| Injectable CPC | Powder phases: ACP, DCPD, SC Liquid phases: deionized water | HAP, SC | Merits: increased injectability and compressive strength, 39.6 MPa. Demerits: the setting time is out of clinical requirement | |
| CPC containing strontium ranelate | Powder phases: partially crystalline calcium phosphate, DCPA, strontium ranelate Liquid phases: deionized water | HAP, DCPA | Merits: good radiopacity and osteogenesis Demerits: the setting time is out of clinical requirement; lower compressive strength, <24 MPa. | |
| Sr-modified premixed CPC | Powder phases: α-TCP, DCPA, SC, HAP, K2HPO4 Liquid phases: liquid consisted of Miglyol 812 with 14.7 wt.% Cremophor ELP and 4.9 wt.% Amphisol A | α-TCP, monetite, HAP, SC | Merits: enhancing mechanical properties; Better radiographic contrast. Demerits: complex powder and liquid phases composite. | |
| A Sr-containing bioactive bone cement | Powder phases: Sr-HAP, fumed silica, benzoyl peroxide Liquid phases: a resin blend (Bisphenol A diglycidylether methacrylate, triethylene glycol dimethacrylate, poly(ethylene glycol) methacrylate, and | Sr-HAP, resin | Merits: setting time, 15∼18 min; compressive strength, 40.9 MPa; bending strength, 31.3 MPa; Bending modulus, 1,408 MPa. Demerits: complex liquid phase composite. | |
| Sr-doped CPC | Powder phases: TTCP, DCPA, SC Liquid phases: ultrapure water | HAP, TTCP, SC | Merits: promoting osteogenic activity. Demerits: the data about its physicochemical properties and | |
| Sr-doped injectable bone cement | Powder phases: Sr-β-TCP, MCPM Liquid phases: water | DCPD, monetite, unreacted β-TCP | Merits: improved injectability; enhanced compressive strength. Demerits: | |
| A novel injectable collagen-Sr-containing CPC | Powder phases: partially crystalline calcium phosphate, DCPA, modified starch Liquid phases: deionized water with type I collagen | HAP | Merits: improved antiwashout property and injectability; higher compressive strength, 21∼48 MPa. Demerits: | |
| Novel injectable Sr-hardystonite phosphate cement | Powder phases: Sr-doped hardystonite, NaH2PO4, Na2B4O7⋅10H2O Liquid phases: deionized water | Sr-doped hardystonite, willemite, silica | Merits: good injectability and handling properties. Demerits: | |
| Sr releasing HAP forming cements | Powder phases: Sr-DCPD, TTCP Liquid phases: DI water or a 1.25% Na2HPO4 solution | Sr-HAP, TTCP | Merits: | |
| Novel Sr containing bioactive glass based CPC | Powder phases: glass (SiO2-P2O5-CaO-SrO-Na2O), Ca(H2PO4)2 Liquid phases: 2.5% Na2HPO4 solution | Sr-HAP | Merits: increasing radiopacity. Demerits: lower compressive strength, <12.5 MPa; longer final setting time. | |
| Sr and hydroxyl ion co-releasing radiopaque HAP cement | Powder phases: Sr-TTCP Liquid phases: 1 M Na2HPO4 and 10 wt.% citric acid | HAP, unreacted TTCP | Merits: | |
| Sr-incorporated biphasic CPC | Powder phases: Sr-β-TCP, TTCP Liquid phases: PA | Sr-β-TCP, Sr-HAP | Merits: suitable operational properties; excellent washout resistance; |
Syntheses of various α-TCP or Sr-α-TCP.
| Sample name | Composition of starting powder | Mean size of the grounded α-TCP particles |
| SC:DCPA:CC | ||
| 0%Sr-α-TCP | 0:2:1 | 7.9 ± 2.3 μm |
| 8.3%Sr-α-TCP | 0.25:2:0.75 | 8.3 ± 1.9 μm |
| 16.7%Sr-α-TCP | 0.50:2:0.50 | 9.5 ± 2.6 μm |
Compositions of various cements and pH values for the SBF after different-sample immersion.
| Sample name | Cement powder | Sr/(Sr+Ca) | pH values for the SBF after different samples immersion | |
| (molar ratio: A:B = 2:1) | ||||
| A | B | |||
| 0Sr-CPC | 0%Sr-α-TCP | TTCP | 0% | 7.430 |
| 5Sr-CPC | 8.3%Sr-α-TCP | TTCP | 5% | 7.433 |
| 10Sr-CPC | 16.7%Sr-α-TCP | TTCP | 10% | 7.537 |
Hydration parameters of various Sr-CPC cements and their effects on the setting time.
| Sample name | L.C. (mol L–1) | P/L ratio | Sr/(Sr+Ca) (×100%) | Setting time (min) | |
| 0Sr-CPC-a | 0.75 | 1.8 | 0% | 1.5 ± 0.2 | 7.0 ± 0.3 |
| 5Sr-CPC-b | 0.75 | 1.8 | 5% | 1.5 ± 0.1 | 7.5 ± 0.5 |
| 10Sr-CPC-c | 0.75 | 1.8 | 10% | 1.5 ± 0.1 | 8.0 ± 0.1 |
| 10Sr-CPC-d | 0.5 | 2.0 | 10% | 2.0 ± 0.2 | 16.0 ± 0.1 |
| 10Sr-CPC-e | 1.0 | 1.6 | 10% | 1.0 ± 0.1 | 4.0 ± 0.4 |
FIGURE 1The XRD patterns of α-TCP containing different Sr contents: (a) α-TCP; (b) 8.3%Sr-α-TCP; and (c) 16.7%Sr-α-TCP.
FIGURE 2The XRD pattern of Ca4(PO4)2O.
FIGURE 3XRD patterns of various Sr-CPC samples after immersed in SBF at 37°C for 72 h: (a) 0Sr-CPC-a; (b) 5Sr-CPC-b; and (c) 10Sr-CPC-c.
FIGURE 4Compressive strength values of Sr-CPC cements with different hydration parameters listed in Table 4 after immersed in SBF at 37°C for 72 h: (a) 0Sr-CPC-a; (b) 5Sr-CPC-b; (c) 10Sr-CPC-c; (d) 10Sr-CPC-d; and (e) 10Sr-CPC-e.
FIGURE 5The SEM morphologies in the typical areas on the fractured surfaces of various Sr-CPC cements after immersed in SBF at 37°C for 72 h: (A,D) 0Sr-CPC-a; (B,E) 5Sr-CPC-b; and (C,F) 10Sr-CPC-c.
EDS data on the surface of the ceramic-like particles in the 10Sr-CPC-c cement after being immersed in SBF at 37°C for 72 h.
| Element | Weight % | Atomic % |
| 41.14 | 63.46 | |
| 18.75 | 14.94 | |
| Ca | 30.83 | 18.99 |
| Sr | 9.28 | 2.61 |
| Total | 100.00 | 100.00 |
FIGURE 6The real-time XRD patterns of the 10Sr-CPC-c samples after immersed in SBF.
FIGURE 7The real-time FESEM photographs of 10Sr-CPC-c samples after hydrating in SBF for different time: (A) 30 min; (B) 1 h; (C) 2 h; (D) 6 h; (E) 10 h; (F) 15 h; (G) 24 h; and (H) 72 h.
FIGURE 8Compressive strength evolution curves of the 10Sr-CPC-c samples immerse in SBF for different hydration stages.
FIGURE 9RGR of MC3T3-E1 cells cultured in different concentrations of extract for (A) 1 day and (B) 3 days.
FIGURE 10Cell number of MC3T3-E1 cells proliferated on the surface of the samples for 1, 4, and 7 days.